The Times Australia
News From Asia

.
Times Media

.

The United Laboratories International Holdings Limited Applies for the Clinical Trial of its Class 1 Innovative New Drug UBT251 Injection

HONG KONG SAR - Media OutReach - 20 June 2023 - On 15 June 2023, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of The United Laboratories International Holdings Limited ("TUL", the "Company" or the "Group"; Stock code: 3933), one of the leading pharmaceutical product manufacturers in the PRC, applied for the clinical trial of its self-developed class 1 innovative new drug UBT251 Injection on indications of adult type 2 diabetes, weight management and nonalcoholic fatty liver/nonalcoholic steatohepatitis ("NASH") and obtained the acceptance and payment notices by China National Medical Products Administration.



The Company is currently the first enterprise in China and the second enterprise in the world to apply for the clinical trial of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) prepared by chemical synthesis peptide.

UBT251 is a long-acting polypeptide drug that stimulates triple-target receptors for GLP-1/GIP /GCG simultaneously. By acting on GLP-1 receptors, GIP receptors and GCG receptors, UBT251 promotes insulin secretion, regulates appetite and energy metabolism, reduces blood glucose and weight, and improves liver steatosis. Preclinical studies in various animal models have proven that UBT251 significantly reduces blood glucose and weight, improves liver steatosis and fibrosis, and that it outperforms the marketed single-target GLP-1 receptor drug Semaglutide and the dual-target GLP-1/GIP drug Tirzepatide in the in-vivo treatment of model animals.

The product is expected to be beneficial for the treatment of patients with various metabolic disorders such as type 2 diabetes, overweight/obesity and NASH, when administered once a week by subcutaneous injection. At present, the fastest progress in the R&D of the same target drugs, both domestic and abroad, has just announced the initiation of phase III clinical trials.

Mr. Tsoi Hoi Shan, Chairman of the Group said that, "TUL has focused on the field of diabetes for several years and is one of the few pharmaceutical companies in China that owns both second and third generation insulin products. As the Group's biopharmaceutical R&D headquarters, The United Bio-Technology specialises in the research and development of drug products for energy metabolism, inflammation and autoimmune diseases. The primary mission of United Bio-Technology is the research and development of high-end biological drugs for the treatment of major chronic diseases. The United Bio-Technology's self-developed class 1 innovative new drug UBT251 Injection fully demonstrates the Group's innovation and R&D capability in biopharmaceutical industry. In the future, we will continue to actively promote the progress of new drug projects, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders."

Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About The United Laboratories International Holdings Limited (TUL)

TUL is one of the leading comprehensive pharmaceutical companies in China, principally engaged in the R&D, manufacturing and selling of finished products, bulk medicines and intermediate products. Its products include drugs for human use and animal healthcare. The Group has six production bases, and its sales teams for intermediate products, bulk medicines and finished products formed a broad sales network covering China and the rest of the world. Currently, TUL is one of the few pharmaceutical companies in China that owns both second and third generation insulin products. The Group is presently a constituent of the Hang Seng Composite Index Series and maintains MSCI ESG rating at A, which is an industry-leading rating.

The Times Features

Joykids Australia Presents the Joykids Family Rave: A Weekend Adventure Like No Other

Get ready to kick off the first day of summer and the festive season with an unforgettable family adventure! Joykids Australia is excited to announce the Joykids Family Rave—an...

New study suggests weight loss drugs like Ozempic could help with knee pain. Here’s why there may be a link

The drug semaglutide, commonly known by the brand names Ozempic or Wegovy, was originally developed[1] to help people with type 2 diabetes manage their blood sugar levels. How...

Maintaining Your Pool After a Marble Interior Upgrade

After upgrading your pool with a marble interior, it’s crucial to understand that maintenance is key to preserving its elegance and longevity. You’ll want to regularly skim for d...

Labor using explanatory document to hide true powers of Misinformation Bill

The opinions and commentary of individuals could be deemed misinformation under Labor’s proposed legislation changes, according to James McComish of Victorian Bar. Appearing in...

Hotel Indigo launches limited-edition candle collection inspired by local neighbourhoods across ANZ

Hotel Indigo, part of IHG Hotels & Resorts' luxury and lifestyle portfolio, is releasing a limited-edition candle collection inspired by the unique neighbourhoods its hotel...

Kyndryl ANZ appoints new Head of Strategic Partnerships and Alliances

Former Head of Marketing to lead and grow Kyndryl’s local channel ecosystem and bolster technological capabilities Kyndryl has strengthened its local leadership team with the ...

Times Magazine

Key Things To Do Before Choosing A Funeral Director

When it comes to planning a funeral, there are many aspects involved in ensuring a smooth-sailing burial service or wake. However, it can get overwhelming to organise a funeral on your own while grieving, especially if the deceased is your loved on...

InVideo Review : Video Creation Tools

So, you have the best and the most exclusive idea for your brand story, and you cannot wait to show this to the world. The best way to put your brand story across is a video, but you hesitate because making and editing a video are ordeals. The e...

Microbes living on air a global phenomenon

UNSW researchers have found their previous discovery of bacteria living on air in Antarctica is likely a process that occurs globally, further supporting the potential existence of microbial life on alien planets.   In their first follow-up t...

From Grease to Gleam: Unveiling the Secrets of Oven Cleaning

A sparkling clean oven is a thing of beauty. It's also a sign of a well-maintained kitchen. But let's be honest: oven cleaning is not exactly the most fun task. It can be time-consuming and messy, and it's easy to get discouraged. But don't despair...

New household battery incentives now available for NSW

Residents across the state can take advantage of the NSW Government's new incentive to make battery storage more affordable. Installing more batteries across NSW will enable homes and businesses to maximise their use of generated solar energy, lo...

10 Essay Help Tips to Share with Friends

Are you someone struggling with writing essays? A well-written essay is sometimes a challenging task. But you are not alone in the journey of essay writing.  You can't always create an interesting essay as it calls for a flow of creativity. A lot ...